Thuja Capital

Thuja Capital is an early-stage venture capital firm specializing in medical product innovations, including therapeutics, medical devices, and digital health solutions. The firm is headquartered in Utrecht, Netherlands, and focuses on companies that develop clinically validated products with demonstrable benefits for both patients and healthcare professionals. Their investment philosophy centers on backing ventures with strong scientific foundations and clear potential for meaningful clinical impact.

The firm typically engages from seed through Series B funding rounds, with initial investments ranging from €500,000 to €5 million and additional capital reserved for follow-on participation. Thuja Capital has developed a strong track record of nurturing healthcare startups through critical development milestones, regulatory challenges, and successful market entry strategies. Their portfolio includes numerous companies that have achieved significant clinical validations, regulatory approvals, and commercial partnerships, reinforcing Thuja's position as a value-adding investor in the European healthcare innovation ecosystem.

In December 2021, Thuja Capital announced the final close of its Thuja Capital Healthcare Fund III at €76 million. This fund focuses on investing in early-stage companies developing novel therapeutics, medical devices (including digital health), or nutraceuticals based in the Netherlands, Belgium, or Germany. The fund aims to identify early-stage investment opportunities, often at an academic project or spin-off stage, and work actively with management to develop initial preclinical proof of concept and attract follow-on investment rounds, with the goal of realizing meaningful healthcare impact.